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Abstract: BACKGROUND: Many patients with an exacerbation of chronic obstructive pulmonary disease
(COPD) are treated with antibiotics. However, the value of antibiotics remains uncertain as systematic
reviews and clinical trials have shown conflicting results. OBJECTIVES: To assess the effects of an-
tibiotics in the management of acute COPD exacerbations on treatment failure as observed between
seven days and one month after treatment initiation (primary outcome) and on other patient-important
outcomes (mortality, adverse events, length of hospital stay). SEARCH METHODS: We searched the
Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and other electroni-
cally available databases up to September 2012. SELECTION CRITERIA: Randomised controlled trials
(RCTs) in people with acute COPD exacerbations comparing antibiotic therapy and placebo with a
follow-up of at least seven days. DATA COLLECTION AND ANALYSIS: Two review authors indepen-
dently screened references and extracted data from trial reports. We kept the three groups of outpatients,
inpatients and patients admitted to the intensive care unit (ICU) separate for benefit outcomes and mor-
tality because we considered them to be clinically too different to be summarised in one group. We
considered outpatients to have a mild to moderate exacerbation, inpatients to have a severe exacerbation
and ICU patients to have a very severe exacerbation. Where outcomes or study details were not reported
we requested missing data from the authors of the primary studies. We calculated pooled risk ratios
(RR) for treatment failure, Peto odds ratios (OR) for rare events (mortality and adverse events) and
weighted mean differences (MD) for continuous outcomes using fixed-effect models. We used GRADE to
assess the quality of the evidence. MAIN RESULTS: Sixteen trials with 2068 participants were included.
In outpatients (mild to moderate exacerbations), there was evidence of low quality that antibiotics did
statistically significantly reduce the risk for treatment failure between seven days and one month after
treatment initiation (RR 0.75; 95% CI 0.60 to 0.94; I(2) = 35%) but they did not significantly reduce the
risk when the meta-analysis was restricted to currently available drugs (RR 0.80; 95% CI 0.63 to 1.01;
I(2) = 33%). Evidence of high quality showed that antibiotics statistically significantly reduced the risk
of treatment failure in inpatients with severe exacerbations (ICU not included) (RR 0.77; 95% CI 0.65
to 0.91; I(2) = 47%) regardless of whether restricted to current drugs. The only trial with 93 patients
admitted to the ICU showed a large and statistically significant effect on treatment failure (RR 0.19; 95%
CI 0.08 to 0.45; high-quality evidence).Evidence of low-quality from four trials in inpatients showed no
effect of antibiotics on mortality (Peto OR 1.02; 95% CI 0.37 to 2.79). High-quality evidence from one
trial showed a statistically significant effect on mortality in ICU patients (Peto OR 0.21; 95% CI 0.06 to
0.72). Length of hospital stay (in days) was similar in the antibiotics and placebo groups except for the
ICU study where antibiotics statistically significantly reduced length of hospital stay (mean difference
-9.60 days; 95% CI -12.84 to -6.36 days). One trial showed no effect of antibiotics on re-exacerbations
between two and six weeks after treatment initiation. Only one trial (N = 35) reported health-related
quality of life but did not show a statistically significant difference between the treatment and control
group.Evidence of moderate quality showed that the overall incidence of adverse events was higher in the
antibiotics groups (Peto OR 1.53; 95% CI 1.03 to 2.27). Patients treated with antibiotics experienced
statistically significantly more diarrhoea based on three trials (Peto OR 2.62; 95% CI 1.11 to 6.17; high-
quality evidence). AUTHORS’ CONCLUSIONS: Antibiotics for COPD exacerbations showed large and
consistent beneficial effects across outcomes of patients admitted to an ICU. However, for outpatients and
inpatients the results were inconsistent. The risk for treatment failure was significantly reduced in both
inpatients and outpatients when all trials (1957 to 2012) were included but not when the analysis for out-
patients was restricted to currently used antibiotics. Also, antibiotics had no statistically significant effect
on mortality and length of hospital stay in inpatients and almost no data on patient-reported outcomes
exist. These inconsistent effects call for research into clinical signs and biomarkers that help identify
patients who benefit from antibiotics and patients who experience no effect, and in whom downsides of
antibiotics (side effects, costs and multi-resistance) could be avoided.
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A B S T R A C T
Background
Many patients with an exacerbation of chronic obstructive pulmonary disease (COPD) are treated with antibiotics. However, the value
of antibiotics remains uncertain as systematic reviews and clinical trials have shown conflicting results.
Objectives
To assess the effects of antibiotics in the management of acute COPD exacerbations on treatment failure as observed between seven
days and one month after treatment initiation (primary outcome) and on other patient-important outcomes (mortality, adverse events,
length of hospital stay).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and other electronically available
databases up to September 2012.
Selection criteria
Randomised controlled trials (RCTs) in people with acute COPD exacerbations comparing antibiotic therapy and placebo with a
follow-up of at least seven days.
Data collection and analysis
Two review authors independently screened references and extracted data from trial reports. We kept the three groups of outpatients,
inpatients and patients admitted to the intensive care unit (ICU) separate for benefit outcomes and mortality because we considered
them to be clinically too different to be summarised in one group. We considered outpatients to have a mild to moderate exacerbation,
inpatients to have a severe exacerbation and ICU patients to have a very severe exacerbation. Where outcomes or study details were not
reported we requested missing data from the authors of the primary studies. We calculated pooled risk ratios (RR) for treatment failure,
Peto odds ratios (OR) for rare events (mortality and adverse events) and weighted mean differences (MD) for continuous outcomes
using fixed-effect models. We used GRADE to assess the quality of the evidence.
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Main results
Sixteen trials with 2068 participants were included. In outpatients (mild to moderate exacerbations), there was evidence of low quality
that antibiotics did statistically significantly reduce the risk for treatment failure between seven days and one month after treatment
initiation (RR 0.75; 95% CI 0.60 to 0.94; I2 = 35%) but they did not significantly reduce the risk when the meta-analysis was restricted
to currently available drugs (RR 0.80; 95% CI 0.63 to 1.01; I2 = 33%). Evidence of high quality showed that antibiotics statistically
significantly reduced the risk of treatment failure in inpatients with severe exacerbations (ICU not included) (RR 0.77; 95% CI 0.65
to 0.91; I2 = 47%) regardless of whether restricted to current drugs. The only trial with 93 patients admitted to the ICU showed a
large and statistically significant effect on treatment failure (RR 0.19; 95% CI 0.08 to 0.45; high-quality evidence).
Evidence of low-quality from four trials in inpatients showed no effect of antibiotics on mortality (Peto OR 1.02; 95% CI 0.37 to
2.79). High-quality evidence from one trial showed a statistically significant effect on mortality in ICU patients (Peto OR 0.21; 95%
CI 0.06 to 0.72). Length of hospital stay (in days) was similar in the antibiotics and placebo groups except for the ICU study where
antibiotics statistically significantly reduced length of hospital stay (mean difference -9.60 days; 95% CI -12.84 to -6.36 days). One
trial showed no effect of antibiotics on re-exacerbations between two and six weeks after treatment initiation. Only one trial (N = 35)
reported health-related quality of life but did not show a statistically significant difference between the treatment and control group.
Evidence of moderate quality showed that the overall incidence of adverse events was higher in the antibiotics groups (Peto OR 1.53;
95% CI 1.03 to 2.27). Patients treated with antibiotics experienced statistically significantly more diarrhoea based on three trials (Peto
OR 2.62; 95% CI 1.11 to 6.17; high-quality evidence).
Authors’ conclusions
Antibiotics for COPD exacerbations showed large and consistent beneficial effects across outcomes of patients admitted to an ICU.
However, for outpatients and inpatients the results were inconsistent. The risk for treatment failure was significantly reduced in both
inpatients and outpatients when all trials (1957 to 2012) were included but not when the analysis for outpatients was restricted to
currently used antibiotics. Also, antibiotics had no statistically significant effect on mortality and length of hospital stay in inpatients
and almost no data on patient-reported outcomes exist. These inconsistent effects call for research into clinical signs and biomarkers
that help identify patients who benefit from antibiotics and patients who experience no effect, and in whom downsides of antibiotics
(side effects, costs and multi-resistance) could be avoided.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a chronic condition, often caused by smoking, which affects the passage of air in and
out of the lungs. Exacerbations of COPD are defined as a sustained worsening of the patient’s symptoms from their usual stable state
and commonly reported symptoms are worsening breathlessness, cough, increased sputum production and change in sputum colour.
Antibiotics are frequently prescribed for exacerbations in patients with COPD although the cause of exacerbations is often difficult to
determine (viral, bacterial, environmental). We did this systematic review to find out if there is good evidence for using antibiotics for
exacerbations of COPD and if benefits of taking antibiotics in individuals outweigh potential harms for individual patients and the
risks of multi-resistant bacteria to the population.
We found 16 randomised studies compared antibiotics with placebo in a total of 2068 COPD patients who presented with a wide range
of severities of exacerbations. Analyses showed that antibiotics reduce treatment failures (no improvement) compared with placebo in
hospitalised patients with severe exacerbations. In outpatients with mild tomoderate exacerbations, the evidence is more unclear because
analyses showed a reduction of treatment failure when all studies and antibiotics were considered, but analyses did not suggest such
an effect when they were restricted to antibiotics in current use. Length of hospital stay and mortality were not reduced by antibiotics
in hospitalised patients except for those who needed treatment on the intensive care unit. Patients treated with antibiotics experienced
diarrhoea twice as often as patients receiving placebo. Severity of underlying COPD could not be compared across trials because lung
function and other parameters were reported inconsistently between trials.
Current evidence shows that antibiotics reduce treatment failures in patients who are hospitalised for the treatment of a COPD
exacerbation, and to a lesser extent in outpatients. Mortality is only reduced by antibiotics in patients with very severe exacerbations
who need treatment in the intensive care unit. The rather small and inconsistent effects of antibiotics on treatment failure suggest
that antibiotics are effective in some patients but not in all inpatients and outpatients. Future high-quality studies should explore how
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antibiotic therapy may be targeted towards patients who benefit by using clinical signs (e.g. purulent sputum) or biomarkers at the
time when patients present to the primary care doctor or emergency department.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics for exacerbations of chronic obstructive pulmonary disease
Patient or population: pat ients with exacerbat ions of chronic obstruct ive pulmonary disease
Settings: outpat ient and inpat ient reported together in the same table (see subgroups)
Intervention: ant ibiot ics versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Antibiotics versus
placebo
Treatment failure up
to 4 weeks1 Subgroup:
outpatient
275 per 1000 206 per 1000
(165 to 259)
RR 0.75
(0.60 to 0.94)
931
(7 studies)
⊕⊕©©
low 2,3
Antibiot ics:
- amoxicill in-clavulanic
acid
- trimethoprim/
sulphamethoxazole
- oxytetracycline
- amoxicillin
- amoxicillin and co-tri-
moxazol
Treatment failure up to
4 weeks1
Subgroup: inpatient
520 per 1000 401 per 1000
(338 to 473)
RR 0.77
(0.65 to 0.91)
612
(4 studies)
⊕⊕⊕⊕
high 4
Antibiot ics:
- amoxicill in-clavulanic
acid and trimethoprim/
sulphamethoxazole
- doxycycline
- tetracycline hy-
drochloride or chloram-
phenicol
- penicill in and strepto-
mycin
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Treatment failure up to
4 weeks1
Subgoup: ICU
565 per 1000 107 per 1000
(45 to 254)
RR 0.19
(0.08 to 0.45)
93
(1 study)
⊕⊕⊕⊕
high
Antibiot ics:
- of loxacine
All- cause mortality
Subgroup: inpatients
35 per 1000 36 per 1000
(13 to 92)
OR 1.02
(0.37 to 2.79)
531
(4 studies)
⊕⊕©©
low 5,6
Antibiot ics:
- tetracycline hy-
drochloride or chloram-
phenicol
- penicill in and strepto-
mycin
- chloramphenicol
- doxycycline
All- cause mortality
Subgroup: ICU
217 per 1000 55 per 1000
(16 to 167)
OR 0.21
(0.06 to 0.72)
93
(1 study)
⊕⊕⊕⊕
high 7
Antibiot ics:
- of loxacine
Adverse events - diar-
rhoea
18 per 1000 45 per 1000
(19 to 99)
OR 2.62
(1.11 to 6.17)
698
(3 studies)
⊕⊕⊕⊕
high
Antibiot ics:
- amoxicill in-clavulanic
acid
- amoxicillin
- of loxacine
Adverse events - over-
all (adverse events not
separated)
74 per 1000 109 per 1000
(76 to 154)
OR 1.53
(1.03 to 2.27)
1243
(5 studies)
⊕⊕⊕©
moderate 8
Antibiot ics:
- amoxicill in-clavulanic
acid
- doxycycline
- amoxicillin
- of loxacine
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; ICU: intensive care unit ; OR: odds rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
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Very low quality: We are very uncertain about the est imate.
1 no resolut ion or deteriorat ion af ter trial medicat ion of any durat ion or death when explicit ly stated due to exacerbat ion or
addit ional course of ant ibiot ics.
2 (- 1 inconsistency). Discrepancy between the stat ist ical signif icance of the meta-analysis that includes all t rials (RR 0.75;
95% CI 0.60 to 0.94) vs. the meta-analysis that is restricted to current ly used drugs (amoxicillin-clavulanic acid, trimethoprim/
sulphamethoxazole, doxycycline, penicill in; RR 0.80; 95% CI 0.63 to 1.01).
3 (-1 lim itat ions). For one trial (Blasi) not all results are available.
4 (no downgrading). The heterogeneity was caused by two small t rials that contribute only 14% to the pooled est imate. Two
larger trials have the most weight in the meta-analysis and show almost ident ical point est imates, therefore we did not
downgrade for inconsistency.
5 (-1 inconsistency). Substant ial heterogeneity across trials with the largest trial showing an increase in mortality and the
three small t rials suggest ing a decrease in mortality.
6 (- 1 imprecision). Wide 95% CI that precludes any conclusion about the ef fects of ant ibiot ics on mortality in inpat ients.
7 (no downgrading). The CI is relat ively wide; however, because the upper lim it of the 95% CI (0.72) as the most conservat ive
ef fect est imate shows an at least moderate ef fect of ant ibiot ics on mortality we did not downgrade.
8 (- 1 imprecision). Lower lim it of 95% CI is very close to 1.0 and it is uncertain if lower lim it would be below 1.0 with addit ional
trials.
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B A C K G R O U N D
The prescription of antibiotics for the treatment of exacerbations
in patients with chronic obstructive pulmonary disease (COPD)
has been, and continues to be, controversial. This controversy is
largely based upon data suggesting that only about half of the ex-
acerbations are of bacterial origin while other causes include vi-
ral infections or environmental irritants (Patel 2002; Seemungal
2001; Sethi 2004). One study by Bafadhel 2011 suggested that
most exacerbations can be categorised as either bacteria-predom-
inant, eosinophil-predominant, virus-predominant and pauci-in-
flammatory and thus may be susceptible to antibiotics or corticos-
teroids or, in the future, to newly developed antiviral drugs.
Antibiotics are widely prescribed (Jones 2008; Pretto 2012). Rea-
sons for using antibiotics include the belief that the origin of an
exacerbation is most likely to be a bacterial infection but also to
’be on the safe side’ and prevent complications of an exacerbation
such as pneumonia. Since side effects of antibiotics are mostly rela-
tively minor, the potential benefits of antibiotics may often appear
to outweigh its harms. The most important arguments against
inappropriate use and overuse of antibiotics are the worldwide
growing problem of multi-resistance (WHO factsheet no. 194),
polypharmacy and costs. Current guidelines (GOLD 2011; NICE
2010) do not recommend antibiotics in general but recommend
antibiotic therapy if all three cardinal symptoms (increased dysp-
noea, sputum and cough) exist or with two of the three cardinal
symptoms, if increased purulence is one of them, which may or
may not be indicative of a bacterial exacerbation. However, there
is currently no high-quality evidence to support this recommen-
dation. In addition, healthcare providers may not always see that
sputum and description of the patient may be unreliable.
Why it is important to do this review
There are several important reasons to conduct this systematic re-
view. A systematic review of the literature informs patients, health-
care providers and clinical practice guideline developers in a trans-
parent way (to minimise bias) about the effects of antibiotics
on patient-important outcomes. This is important since antibi-
otics are likely to be perceived as beneficial in clinical practice by
patients and healthcare providers because most patients recover
within some weeks. However, only placebo-controlled trials can
determine the cause of such recovery, which might be because of
the natural recovery from exacerbations (i.e. without antibiotics),
the effects of antibiotics or some other concomitant treatments
such a systemic corticosteroids. Knowledge about the effects of
antibiotics compared to placebo is also important to appreciate
the results of the many randomised trials that compare different
antibiotics. Only if antibiotics are effective at all will such head-
to-head trials provide useful information (Puhan 2008).
There is growing recognition that COPD is a very heterogeneous
disease (Garcia-Aymerich 2011) and exacerbations are heteroge-
neous events (Bafadhel 2011). This systematic review may also
provide some guidance on the effects of antibiotics in different
patients. Finally, systematic reviews provide useful guidance on
how strong recommendations can be made for clinical practice
and where more research is needed. Thus, given the uncertainties
about the use of antibiotics for COPD exacerbations, this system-
atic review provides useful information in several respects.
This review is partly based on the protocol of a withdrawn
Cochrane review on the same topic (Ram 2006) and the standard
methods of the Cochrane Collaboration.
O B J E C T I V E S
To assess the effects of antibiotics in the management of acute
COPD exacerbations on treatment failure as observed between
seven days and one month after treatment initiation (primary out-
come) and on other patient-important outcomes (mortality, ad-
verse events, length of hospital stay).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) using an antibiotic in the
treatment group and placebo in the control group.
Types of participants
Patients with acute exacerbations of COPD (defined as a worsen-
ing of a previous stable situation with symptoms such as increased
dyspnoea, increased cough, increased sputum volume or change
in sputum colour).
We considered studies eligible if more than 90% of patients had a
clinical (physician-based) diagnosis ofCOPDor, ideally, spiromet-
rically confirmed COPD and patients were over 40 years of age.
For trials with physician-based diagnosis of COPD (also chronic
bronchitis in older studies) we only considered studies when over
90% of patients had a smoking history. We accepted physician-
based diagnosis of COPD because spirometry has limited value
during an acute exacerbation of COPD and because restricting
the systematic review to patients with spirometrically confirmed
COPD would be limited to trials where patients at risk for exac-
erbations were enrolled in stable state and randomised when they
actually suffered from an exacerbation. We excluded studies of pa-
tients with acute bronchitis, pneumonia, asthma or bronchiecta-
sis.
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Types of interventions
Oral or intravenous antibiotics administered daily for a minimum
period of at least two days. All studies using antibiotics for the
prevention of exacerbations were excluded as this addresses a dif-
ferent question. Whether or not oral corticosteroids were used ad-
ditionally was not an inclusion or exclusion criterion.
Types of outcome measures
Primary outcomes
• Treatment failure as observed between seven days and one
month after treatment initiation (no resolution or deterioration
of symptoms after trial medication of any duration or death
when explicitly stated due to exacerbation or additional course of
antibiotics or other medication).
Secondary outcomes
• Treatment failure as observed between seven and 14 days
after treatment initiation.
• All-cause mortality.
• Duration of hospital admission (for inpatients).
• Admission to an intensive care unit (ICU).
• Re-exacerbations within ≥ two to six weeks since beginning
of index exacerbation (inpatient or outpatient treatment, rates or
time to event).
• Adverse events.
• Improvement in dyspnoea.
• Hospital admission.
• Health-related quality of life or functional status measures.
• Time off work.
Search methods for identification of studies
Electronic searches
We identified trials using theCochrane Airways Group Specialised
Register of trials, which is derived from systematic searches of
bibliographic databases including the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals and meeting abstracts (see Appendix 1 for further
details). All records in the Specialised Register coded as ’COPD’
were searched using the following terms:
• antibiotic* or penicillin* or amoxycillin or ampicillin or
cefalosporin* or cefaclor or cefalexine or cephalotin or cefazolin
or cefixime or cefotaxime or cefpodoxime or cephradine or
ceftizoxime or ceftriaxone or cefuroxime or tetracyclin* or
demeclocycline or doxycycline or minocycline or oxytetracycline
or *cycline or macrolides or azithromycin or clarithromycin or
dirithromycin or erythromycin or roxithromycin or
telithromycin or troleandomycin or *thromycin or (*mycin) or
fluoroquinoln* or ciprofloxacin or gatifloxacin or gemfloxacin or
grepafloxacin or levofloxacin or lomefloxacin or moxifloxacin or
ofloxacin or sparfloxacin or trovafloxacin or *floxacin or
chloramphenicol or clindamycin or trimethoprim or
sulfamethxazole or cotrimoxazole or carbapenem* or meropenem
or imipenem.
A search of ClinicalTrials.gov was also conducted. Databases were
searched from 2005 (their inception) to April 2012. The search
from inception to 2006 is described elsewhere (Puhan 2007).
There was no restriction on the language of publication.
Searching other resources
Bibliographies of each selected RCT, and other systematic reviews,
were scrutinised for additional potential RCTs. Authors of iden-
tified RCTs and pharmaceutical companies producing antibiotics
were contacted for other published, unpublished or ongoing stud-
ies.
Data collection and analysis
Selection of studies
Two review authors independently assessed the titles and abstracts
of all identified citations without imposing any language restric-
tions. The review authors then independently evaluated the full
text of articles that seemed potentially eligible by one of the review
authors. Any disagreements were resolved by consensus with close
attention to the inclusion/exclusion criteria. All studies that did
not fulfil all of the criteria were excluded and their bibliographic
details listed, with the reason for exclusion.
Data extraction and management
Two review authors independently abstracted data, which was
double checked and entered into Review Manager 5.1 software
(RevMan 2011).
Assessment of risk of bias in included studies
We assessed the risk of bias using the domain-based approach de-
scribed in theCochrane Handbook of Systematic Reviews of Interven-
tions (Higgins 2011). The domains included an assessment of how
the random sequence was generated, allocation concealment was
ensured, blinding of participants and personnel and outcome as-
sessors was applied, and whether an intention-to-treat analysis was
used. Any disagreements between review authors were resolved by
discussion. In addition, we used the GRADE approach to deter-
mine the quality of evidence using the standard criteria risk of bias,
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inconsistency, indirectness, imprecision and other biases (Guyatt
2011).
We generated a ’Summary of findings table’ for the most impor-
tant outcomes (treatment failure, all-cause mortality, overall ad-
verse events and diarrhoea) (Summary of findings for the main
comparison) and used GRADEpro software and recommenda-
tions in the Cochrane Handbook of Systematic Reviews of Interven-
tions (Higgins 2011) to assess the quality of evidence.
Measures of treatment effect
We calculated pooled risk ratios (RR), Peto odds ratios (OR) for
rare events and weighted mean differences (MD) for continuous
outcomes.
In trials with two groups receiving different antibiotics, we treated
these groups as one group if the effects of the two antibiotics did
not differ in a statistically significant or clinically important way.
Dealing with missing data
When necessary we contacted study authors in order to obtain
further information about their trials.
Assessment of heterogeneity
We kept the three groups of outpatients, inpatients and patients
admitted to the ICU separate for most analyses except for adverse
events because we considered them to be clinically too different
to be summarised in one group. We considered outpatients to
have a mild to moderate exacerbation, inpatients to have a severe
exacerbation and ICU patients to have a very severe exacerbation
(event-based definitions of severity of exacerbations). Within the
analysis of outpatients and inpatients we used the heterogeneity
Chi2 statistic to assess statistical heterogeneity and expressed it by
the I2 statistic.
Assessment of reporting biases
For trials published after 1990 we tried to find the trial registration
information and assessedwhether all outcomes specified therewere
reported.
Data synthesis
We used fixed-effect models (or random-effects model if statisti-
cal heterogeneity with I2 > 50% was observed) to calculate mean
differences for continuous outcomes or inverse-variance weighted
pooled RRs. For rare events and trials with similar size of treat-
ment groups we used Peto’s method to pool ORs. We also calcu-
lated number needed to treat for an additional beneficial outcome
(NNTB) and 95% confidence interval (CI) and number needed
to treat for an additional harmful outcome (NNTH). These were
calculated using the following formula: NNT = 1/ [CER * (1 -
RR)] (where CER = control event rate).
Subgroup analysis and investigation of heterogeneity
As explained above, we kept as a marker of the severity of exacer-
bation outpatients, inpatients and patients admitted to the ICU
separate for all benefit outcomes.
Sensitivity analysis
In a sensitivity analysis we restricted the analyses to trials that eval-
uated at least one antibiotic that is still in current use (amoxi-
cillin-clavulanic acid, trimethoprim/sulphamethoxazole, doxycy-
cline, penicillin).
R E S U L T S
Description of studies
Results of the search
Searches to 2006
The electronic search of the former non-Cochrane review con-
ducted by this author team (Puhan 2007) yielded 765 references.
After assessing references on the basis of title and abstract, two
review authors independently scanned the full text of 35 studies of
the electronic search and additional 30 studies that were identified
through handsearching. Four studies were ongoing trials (ABC
2009; Fartoukh 2004; NCT00170222; NCT00255983). Thir-
teen studies were included (Allegra 1991; Alonso Martinez 1992;
Anthonisen 1987; Berry 1960; Elmes 1957; Fear 1962; Jørgensen
1992; Manresa 1987; Nouira 2001; Petersen 1967; Pines 1968;
Pines 1972; Sachs 1995).
Searches from 2005 to 2012
We identified 226 citations from the update search (2005 to 2012)
of electronic databases.We retrieved 25 full texts andhandsearched
nine protocols on www.clinicaltrials.gov. Out of this search we
identified two eligible trials (Daniels 2010; Llor 2012) and through
handsearching we identified one additional trial (ABC 2009) (see
Figure 1).
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Figure 1. Study flow diagram.
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Included studies
We included 16 studies on 2068 participants. Out of the 16
included studies, nine trials included outpatients (ABC 2009;
Allegra 1991; Anthonisen 1987; Berry 1960; Elmes 1957; Fear
1962; Jørgensen 1992; Llor 2012; Sachs 1995), six trials included
patients admitted to a hospital (Alonso Martinez 1992; Daniels
2010;Manresa 1987; Petersen 1967; Pines 1968; Pines 1972) and
one trial included patients admitted to a medical ICU (Nouira
2001). The studies were, on average, of small sample size with a
range from 19 to 310 included patients. Severity of underlying
COPD could not be compared across trials because lung function
and other parameters were reported inconsistently between trials.
Twelve trials were reported as full reports in English language jour-
nals, one trial was published in Spanish (Alonso Martinez 1992),
one in Italian (Allegra 1991), one trial was reported as a confer-
ence proceeding and medical thesis (ABC 2009) and one trial was
reported as a clinical letter to a major journal (Manresa 1987).
One trial (Allegra 1991) only entered the analyses on adverse ef-
fects because it reported only on treatment failure within five days
of treatment initiation. We made attempts to retrieve the data on
treatment failure within two weeks, which was assessed but not
reported (personal communication with Dr Blasi, March 2006)
but the data were not made available to us. Further details on in-
cluded studies are shown in the table Characteristics of included
studies and a summary of the interventions across studies can be
found in Table 1.
Excluded studies
We excluded most trials because they compared different types
of antibiotics to each other and had no placebo arm (see
Characteristics of excluded studies; Figure 1). One study was iden-
tified as an ongoing study (NCT01091493) that had just started.
Risk of bias in included studies
Overall therewas relatively little risk of bias (see Figure 2). Random
sequence generation, blinding of participants and personnel, and
intention-to-treat analysis was correctly performed and reported
by 80% of the studies. Allocation concealment and blinding of
outcome assessment was correctly performed and reported by 56%
of the studies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
for exacerbations of chronic obstructive pulmonary disease
Primary outcome: treatment failure between seven
days and one month of treatment initiation
Eleven studies with 1326 patients reported on this outcome
(Figure 3). The follow-up period for these studies to assess
treatment failure ranged from eight to 28 days. In some stud-
ies treatment failure outcome was patient reported (ABC 2009;
Anthonisen 1987; Berry 1960; Daniels 2010; Elmes 1957;
Jørgensen 1992; Sachs 1995), while in two trials it was provider
11Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
reported (Llor 2012; Pines 1968), defined by an additional course
of antibiotics (Alonso Martinez 1992; Pines 1972) or a combined
end point of additional antibiotics and death (Nouira 2001). As
pre-defined we analysed treatment separately for outpatients, in-
patients and patients admitted to the ICU.
Figure 3. Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.1 Treatment failure up to 4
weeks (no resolution or deterioration after trial medication of any duration or death when explicitly stated
due to exacerbation or additional course of antibiotics).
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In outpatients (seven trials; 931 participants; Figure 3) antibiotics
statistically significantly reduced the risk for treatment failure (RR
0.75; 95% CI 0.60 to 0.94; I2 = 35%) with an NNTB of 13
(95% CI 8 to 46). Antibiotics had a statistically significant effect
in inpatients (four trials; 612 participants) (RR 0.77; 95%CI 0.65
to 0.91; I2 = 47%) with an NNTB of 10 (95% CI 6 to 45). In
the ICU trial with 93 participants antibiotics showed a statistically
significant effect (RR 0.19; 95% CI 0.08 to 0.45) with an NNTB
of 2 (95% CI 2 to 3).
Restricting the analysis to currently used drugs (amoxicillin-clavu-
lanic acid, trimethoprim/sulphamethoxazole, doxycycline, peni-
cillin) gave a different effect compared to the unrestricted analyses
for outpatients (RR 0.80; 95% CI 0.63 to 1.01; Figure 4) with
a non-statistically significant effect. In inpatients, the results were
similar (RR 0.71; 95% CI 0.55 to 0.92).
Figure 4. Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.2 Treatment failure within 4
weeks - current drugs only.
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Adverse events
The pooled analysis includes only trials that evaluated currently
used antibiotics.
Diarrhoea
Three studies with 398 patients (Allegra 1991; Jørgensen 1992;
Nouira 2001) provided data on the number of patients experienc-
ing diarrhoea. Figure 5 shows that patients treated with placebo
had a statistically significantly lower chance of diarrhoea compared
to patients treated with antibiotics (Peto OR 2.62; 95% CI 1.11
to 6.17; NNTH of 36; 95% CI 19 to 565).
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Figure 5. Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.3 Adverse events.
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Overall adverse events
Five studies with 1243 patients (Allegra 1991; Daniels 2010;
Jørgensen 1992; Llor 2012; Nouira 2001) provided data on the
overall incidence of adverse events in the study groups. There were
statistically significantly fewer adverse events with placebo (Peto
OR1.53; 95%CI 1.03 to 2.27;NNTH32; 95%CI 16 to 10490).
Other adverse events are shown in Figure 5.
All-cause mortality
Five trials on 624 patients, four inpatient trials (Daniels 2010;
Petersen 1967; Pines 1968; Pines 1972) and one ICU trial (Nouira
2001), reported mortality. There was no statistically significant
effect of antibiotics on mortality for inpatients (Peto OR 1.02;
95% CI 0.37 to 2.79) but there was a statistically significant effect
in ICU patients (Peto OR 0.21; 95% CI 0.06 to 0.72; NNTB 6
(96% CI 3 to 24) (Figure 6).
Figure 6. Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.4 All-cause mortality.
Duration of hospital stay
Three trials with 202 patients reported length of hospital stay
(measured in days). Of these three trials two favoured neither an-
tibiotics nor placebo (AlonsoMartinez 1992;Manresa 1987). The
third trial (Nouira 2001), an ICU trial, clearly favoured antibiotics
(MD -9.60; 95% CI -12.84 to -6.36).
Dyspnoea
Two studies with 300 patients reported dyspnoea at the end of the
study period (ABC 2009; Daniels 2010). There was no significant
improvement in dyspnoea in either trial (outpatients: MD 0.00;
95% CI -0.97 to 0.97; inpatients: MD -0.60; 95% CI -1.27 to
0.07) (Analysis 1.6).
Outcomes with only one included trial
Health-related quality of life
One outpatient trial (ABC 2009)with 35 patients reported health-
related quality of life and showed no statistically significant differ-
ence between the treatment and control group (MD 0.00; 95%
CI -1.79 to 1.79) (Analysis 1.7).
16Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Re-exacerbations
One trial (ABC 2009) with 35 patients reported number of pa-
tients with re-exacerbations within two to six weeks. In the an-
tibiotics group, there were two re-exacerbations compared to one
in the placebo group (RR 1.89; 95% CI 0.19 to 18.97) (Analysis
1.8).
Days off work
Elmes 1957, the oldest trial, reported days off work. The antibi-
otics group had statistically significantly fewer days off work com-
pared with the placebo group (MD -5.18; 95% CI -6.08 to -4.28)
(Analysis 1.9).
Grading
The ’Summary of findings’ table shows that the quality of evi-
dence was low for the effect estimates of antibiotics on treatment
failure in outpatients because of the discrepancy between the sta-
tistical significance of meta-analysis that includes all trials versus
the meta-analysis that is restricted to currently used drugs (amox-
icillin-clavulanic acid, trimethoprim/sulphamethoxazole, doxycy-
cline, penicillin) and because the results from one trial were not
made available by the study authors. For inpatients and patients
admitted to the ICU we considered the results for the outcome
treatment failure to be high. Since there was substantial hetero-
geneity across trials in inpatients that assessed the effects of an-
tibiotics on mortality and because the results were imprecise we
downgraded the quality of evidence to low. The quality of evidence
on the effects of antibiotics on mortality in patients admitted to
the ICU was high. For adverse events, we considered the quality
of evidence to be high for the outcome of diarrhoea but down-
graded the quality of evidence for any adverse events because of
imprecision. It is uncertain if the lower limit of the 95% CI would
be below 1.0 with additional trials.
D I S C U S S I O N
Summary of main results
The meta-analyses showed that antibiotics for acute exacerbations
of COPD reduced treatment failure statistically significantly for
outpatients when all trials from 1957 to 2012 were included but
not when the analyses were restricted to currently used antibiotics.
Antibiotics had a statistically significant effect on treatment fail-
ure in inpatients and patients treated in the ICU. There was a
statistically significant reduction in the risk of mortality among
ICU patients with the use of antibiotics but not for inpatients (no
data for outpatients available). There was a statistically significant
increase in the risk of adverse events with antibiotic use compared
to placebo. Length of hospital stay was not significantly reduced
by antibiotics except for ICU patients. There were few data on
the effects of antibiotics on health-related quality of life or other
patient-reported symptoms.
Overall completeness and applicability of
evidence
The severity of underlying COPD could not be studied as a po-
tential source of heterogeneity. Trials with information on COPD
severity are rare as lung function tests are difficult to perform dur-
ing exacerbations and as lung function results are rarely available
from the pre-exacerbation period. Also, the definitions and clas-
sifications of COPD have changed over the years so that no uni-
form classifications of COPD could be extracted from the studies.
Nevertheless, the results from this review appear to be applicable
to patients with moderate to severe COPD who typically suffer
from exacerbations.
There was no common definition for severity of exacerbation that
was used in the trials. There is uncertainty on the thresholds of
admitting patients to hospital and whether this was comparable
among trials. Thus stratification according to setting is just a proxy
for the severity of exacerbation although such an event-based def-
inition is commonly used in COPD research (Rodriguez-Roisin
2000). Our finding that the effects of antibiotics depend on the
severity of exacerbations is supported by the Anthonisen 1987
trial, which showed a benefit for the most severe exacerbations but
not for mild exacerbations. In contrast, the results of the meta-
analyses for treatment failure in outpatients and inpatients (non-
ICU patients) showed almost identical results. This may suggest
that our conservative approach of keeping outpatients and inpa-
tients separate was not necessary and that there are other determi-
nants of hospital admission than the severity of an exacerbation
only.
Only two small trials reported patient-important outcomes such
as health-related quality of life or days off work, which is heavily
influenced by exacerbations and one of the main targets of COPD
treatments.
With a relatively high NNTH it could be argued that treating
outpatients with antibiotics is not problematic as some may still
benefit. This disregards the consistent and growing problem of
resistance against antibiotics and the need to decrease the over-
utilisation of unnecessary antibiotics (WHO factsheet no. 194).
Overall, there is a strong beneficial effect of antibiotics in ICU
patients. In inpatients and outpatients there is some effect of an-
tibiotics but the effects are small and inconsistent for some out-
comes (treatment failure) and absent for other outcomes (mortal-
ity, length of hospital stay).
Quality of the evidence
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Werestricted our systematic review toRCTs and found16placebo-
controlled RCTs with 2068 patients. Starting with the assumption
that RCTs provide high-quality evidence, we did not downgrade
the quality of evidence for risk of bias for any outcome because the
risk of bias was low for most trials. We downgraded the analyses
for some outcomes for inconsistency, which is not unexpected
given the heterogeneity of patients with COPD. As a consequence
of the small number of patients and events, we downgraded the
quality of evidence for mortality in inpatients. We expect, based
on our assessment of the quality of evidence, that additional trials
could change the results for treatment failure in outpatients and
for mortality in inpatients.
Potential biases in the review process
Although treatment failure is commonly used in meta-analyses, it
is a limitation that definitions of treatment failure differ across tri-
als. It is difficult to standardise the definition of treatment failure
because it may include patient-reported symptoms, clinical signs
and results from laboratory tests or imaging. However, we do not
have reason to believe that different definitions of treatment fail-
ure caused heterogeneity in our meta-analyses. Also, we could not
assess the influence of other factors such as season, co-morbidities
or concurrent medication use such as systemic corticosteroids or
bronchodilators as they were reported inconsistently and to a lim-
ited extent.
A limitation of the present systematic review is publication bias,
which is a potential threat to any systematic review. Studies demon-
strating a positive effect for antibiotics may be more likely to be
published thannegative studies. In order tominimisemissing stud-
ies we used extensive trial search criteria with no language restric-
tions and made every effort to detect any unpublished or ongoing
studies and contacted authors of the included trials, some of whom
provided additional information about their data. However, we
have reasons to believe that the results of two trials are not yet in
the public domain and we, therefore, downgraded the quality of
evidence for the outcome of treatment failure in outpatients.
Agreements and disagreements with other
studies or reviews
Our systematic review is in agreementwith a former review (Puhan
2007), and the findings did not change substantially with the ad-
dition of three new trials (ABC 2009; Daniels 2010; Llor 2012).
We agree with the former Cochrane review on this topic (Ram
2006) on treatment failure in inpatients but we disagree with
several other outcomes and the review’s conclusions. The former
Cochrane reviewused several different outcomes such as peak flow,
lung function, sputum purulence and blood gases, which we be-
lieve are not the important, patient-relevant outcomes to estimate
the value of antibiotics for the management of acute COPD exac-
erbations. Also, the former review included a study that was not
an RCT (Elmes 1965) and excluded a study that actually was an
RCT (Berry 1960). In addition, we were able to obtain COPD-
specific data from one RCT (Sachs 1995) that reported on the
results for both asthma and COPD patients. Also, our results for
mortality in inpatients differ from those of the former Cochrane
review because that review included the Elmes trials (Elmes 1965)
and did not keep ICU and inpatients separate.
The systematic review of Saint 1995 combined results from dif-
ferent outcomes in a meta-analysis. Nevertheless, the authors con-
cluded an overall combined standardised mean effect size estimate
of 0.22 (95% CI 0.1 to 0.34) indicating a small but statistically
significant effect favouring antibiotics over placebo.We think that
combining different outcomes and using standardised effect sizes
is an inappropriate way to pool results.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is continued uncertainty as to whether antibiotics provide
a benefit to COPD patients with acute exacerbations that can be
treated on anoutpatient basis. Current data suggest that antibiotics
do not significantly reduce treatment failure or improve the pa-
tients’ health-related quality of life with currently available antibi-
otics. In patients who need hospital admission for severe exacer-
bations, antibiotics do reduce treatment failures but not the length
of hospital stay or mortality. Finally, antibiotics reduce mortality,
treatment failures and length of hospital stay in patients who need
ICU care. The results of this systematic review provide evidence
for developers of guidelines to consider the evidence base but also
additional factors such as patient preferences, resistance of bacteria
to antibiotics and cost to make practice recommendations.
Implications for research
In the large majority of COPD patients who are treated on an
outpatient basis because of mild to moderate exacerbations addi-
tional placebo-controlled trials could determine the effectiveness
of antibiotics on short- and long-term outcomes and on patient-
important outcomes such as health-related quality of life. It is chal-
lenging to recruit outpatients for placebo-controlled trials because
of widespread beliefs about the positive effects of antibiotics. But
as our review suggests, withholding antibiotics in outpatients and
even in inpatients did not or only slightly increase the risk for
treatment failure and mortality so that placebo-controlled RCTs
are still justifiable.
The conflicting evidence raised discussions about (bio-) markers,
which could predict a bacterial infection and help to select patients
who benefit from antibiotic treatment and save antibiotics in those
who are unlikely to benefit. Sputum purulence is one of the most
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discussed indicators that could be used to guide antibiotic therapy.
It is noteworthy that there are no adequately powered RCTs that
assessed effect modification by the presence or absence of purulent
sputum. Indirect evidence on effect modification is available from
the trials included in this systematic review. Four trials (ABC 2009;
Elmes 1957; Pines 1968; Pines 1972) included patients with pu-
rulent sputum only or positive gram stain, although few details on
how purulent sputum was defined and measured were available.
Of these four trials only one showed a statistically significant effect
on treatment failure (Pines 1968) and the only most recent trial
(ABC 2009) did showed no effects on any of the outcomes. Also,
there is no indication from the trials included in this review that
these trials show results that are different from those trials that
did not restrict the study population to patients with purulent
sputum. Biomarkers may also be promising to guide antibiotic
treatment for COPD exacerbations. C-reactive protein (CRP) or
B-type natriuretic peptide may be promising because they are rel-
atively cheap and easily available in inpatient and outpatient set-
tings (Llor 2012; Daniels 2010b). There are additional candidates
for guiding antibiotic treatment, such as procalcitonin, but their
cost currently limits their use to highly specialised settings.
There are different types of studies that could be done to deter-
mine the potential of clinical signs and biomarkers to guide antibi-
otic therapy for COPD exacerbations. Additional placebo-con-
trolled trials could assess whether the effects of antibiotics (ver-
sus placebo) are different in patients with (or without) purulent
sputum or with different levels of a biomarker. Such trials would
require relatively large sample sizes in order to assess subgroup ef-
fects (effect modification) formally. Alternatively, more pragmatic
trials could be done where physicians are randomised to using or
not using a clinical sign or biomarker to guide the prescription
of antibiotics. Such trials would typically be non-inferiority trials
that aim to show that the clinical benefit is not worse when us-
ing a clinical sign or biomarker but that adverse effects, cost and
bacterial resistance could be limited by less use of antibiotics. One
Cochrane review showed that procalcitonin guidance was not as-
sociated with increased mortality or treatment failure in patients
with acute respiratory infections but significantly reduced overall
antibiotics use (Schuetz 2012). Finally, observational studies may
be used to look into the potential of clinical signs or biomarkers
to predict outcomes of patients with COPD exacerbations. Such
studies could either assess the independent predictive properties of
clinical signs or biomarkers, or compare the outcomes with antibi-
otic treatment versus no antibiotic treatment in patients with or
without a clinical sign or certain biomarker levels while adequately
adjusting for selection mechanisms and confounding. Such ob-
servational studies appear more feasible than additional placebo-
controlled RCTs but theymay often be only hypothesis generating
rather than providing high-quality evidence as a basis for treat-
ment recommendations.
Finally, it would also be important to have more high-quality ev-
idence on the long-term effects (re-exacerbations, health-related
quality of life and mortality) of antibiotics in COPD patients with
mild to moderate exacerbations. Also, head-to-head antibiotic tri-
als continue to be important in COPD patients treated for exac-
erbations in inpatient and ICU settings because the susceptibility
of strains is dynamic and may differ over time and from setting to
setting.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ABC 2009
Methods RCT
Participants Participants: outpatients seen by chest physicians received antibiotic or placebo for mod-
erately severe exacerbations
Inclusion criteria: clinical diagnosis of COPD (GOLD criteria), current or ex-smoker,
aged 40 to 80 years, presenting as an outpatient with signs and symptoms of an exac-
erbation (change in dyspnoea, sputum volume and colour, and cough), able to produce
sputum sample, 1 or 2 of: positive sputum Gram’s stain, clinically relevant decrease in
lung function or ≥ 2 exacerbations in the previous year
Exclusion criteria: pneumonia, exacerbation or use of antibiotics or prednisolone 4weeks
prior to enrolment (except≤ 5mgprednisolone), other disease influencing lung function,
maintenance antibiotics, hypersensitivity to amoxicillin-clavulanic acid, serious medical
or psychiatric co-morbidity, uncontrolled diabetes mellitus, home oxygen therapy
Baseline demographics: 35 patients included; mean age 67 years; 60%male;mean FEV1/
FVC 40%
Spirometrically confirmed COPD: yes
Severity of exacerbation: moderate
Interventions Follow-up: 28 days for primary outcome and 4 months for new exacerbations
Treatment group: amoxicillin-clavulanic acid 1.5 g/day for 7 days and oral prednisolone
30 mg for 7 days
Control group: placebo for 7 days and oral prednisolone 30 mg for 7 days
Outcomes Resolution of exacerbation (patient reported symptom diary)
Relapses of exacerbations within 28 days
Chronic respiratory questionnaire
Clinical COPD questionnaire
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
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ABC 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information to permit judgment of yes or no
Intention-to-treat-analysis Low risk All patients were analysed in the groups to which they were
randomised
Allegra 1991
Methods RCT
Participants Participants: patients recruited from pulmonary departments received antibiotic or
placebo on an outpatient basis in case of self-reportedworsening of respiratory symptoms
Inclusion criteria: aged > 40 years, chronic bronchitis (defined as continuous cough and
expectoration, present for at least 3 months of the year, in more than 2 consecutive years)
, FEV1 < 80% predicted
Exclusion criteria: reversible obstruction, cancer, liver insufficiency, renal insufficiency,
heart failure, pneumonia
Baseline demographics: 335 patients included; mean age 63 years; 73% male; mean
FEV1 1.37 L/s
Spirometrically confirmed COPD: yes
Severity of exacerbation: mild to moderate
Interventions Mean follow-up: 5 days
Treatment group: amoxicillin-clavulanic acid 2 g/day (oral) for 5 days
Control group: placebo for 5 days
Outcomes Treatment success/failure (patient-reported symptoms and clinical signs) at 5 days (not
analysed in this systematic review)
Dyspnoea (not analysed in this systematic review because data were not in format that
we could use)
Adverse events
Notes According to an author of the study (personal communication with Dr. Blasi, March
2006) data after 14 days of follow-up were available but not published and not made
available for this review
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
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Allegra 1991 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Intention-to-treat-analysis High risk Only patients with complete follow-up were analysed
Alonso Martinez 1992
Methods Randomised double-blinded placebo-controlled trial
Participants Participants: patients admitted to hospital with exacerbation (increasing symptoms such
as dyspnoea, sputum volume or cough) of COPD
Inclusion criteria: clinical diagnosis of COPD at the time of hospital admission
Exclusion criteria: antibiotic treatment during the previous 2 weeks, left ventricular
failure, stroke, pneumonia, pneumothorax, non-cutaneous cancer, coma, temperature >
38 °C, psychological disorders related to COPD
Baseline demographics: 90 patients included; mean age 68 years, 84%male, mean FEV1
% predicted (SD) 29.98% (11.07)
Spirometrically confirmed COPD: yes
Severity of exacerbation: severe
Interventions Mean follow-up: 7.2 days
Treatment group: trimethoprim-sulphamethoxazole 1.9 g/day or amoxicillin/clavulanic
acid 1.9 g/day orally for 8 days
Control group: placebo for 8 days
Outcomes Length of hospital stay
Treatment success (use of additional antibiotics)
Re-exacerbations (in 3 months - not analysed in this systematic review)
Notes All patients were treated with theophylline, inhaled bronchodilators and oxygen. If the
numerical score was high or FEV1 < 40% they received, 6-methylprednisolone 0.75 mg/
kg/day
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Arithmetic combination
Allocation concealment (selection bias) Low risk Through hospital pharmacy
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Alonso Martinez 1992 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information provided
Intention-to-treat-analysis Low risk Analysed as intention to treat
Anthonisen 1987
Methods Randomised double-blinded placebo-controlled trial
Participants Participants: 173 patients were recruited from the community with stable COPD. 116
developed exacerbations (increased dyspnoea, sputum volume or sputum purulence) and
each time was randomly assigned to receive antibiotics or placebo
Inclusion criteria: aged > 35 years; clinical diagnosis of COPD, not asthma; FEV1 and
FVC < 70% predicted, TLC > 80%
Exclusion criteria: if FEV1 increased to 80% of predicted post bronchodilator use; other
disease serious enough to influence their quality of life or clinical course (e.g. cancer,
left ventricular failure, stroke) or other disease likely to require antibiotics (e.g. recurrent
sinusitis or UTI)
Baseline demographics: 116 patients included; mean age 67 years, 80% male, mean
FEV1 % predicted (SD): 33.9% (13.7)
Spirometrically confirmed COPD: yes
Severity of exacerbation: mild to moderate
Interventions Follow-up: 21 days
Treatment group: trimethoprim/sulphamethoxazole 1.9 g/day or amoxicillin 1 g/day or
doxycycline 0.1 to 0.2 g/day orally for 10 days
Control group: placebo for 10 days
Outcomes Treatment failure (patient-reported symptoms)
Side effects (% of exacerbations with side effects)
Notes The analysis was based on number of patients with first exacerbations (only first exacer-
bation). Side effects were not analysed as they were expresses as % of all exacerbations
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random schedule
Allocation concealment (selection bias) Unclear risk Not reported
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Anthonisen 1987 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Neither patients nor medical staff knew
which medication was active”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Medical staff ”
Intention-to-treat-analysis Low risk Analysed as intention to treat
Berry 1960
Methods RCT
Participants Participants: patients at general practitioner visit for new or aggravated respiratory symp-
toms
Inclusion criteria: chronic bronchitis (persistent or recurrent cough with diffuse physical
signs in the chest, in which X-ray had excluded other disease) with exacerbation (wors-
ening characterised by 1 or more of the following: increased cough, increased volume of
sputum, increased purulence of sputum, increased breathlessness or fever)
Exclusion criteria: none
Baseline demographics: 58 patients included; mean age 59 years, 53% male, FEV1 not
reported
Spirometrically confirmed COPD: no
Severity of exacerbation: mild to moderate
Interventions Mean follow-up: 14 days
Treatment group: oxytetracycline 1 g/day (oral) for 5 days
Control group: placebo for 5 days
Outcomes Treatment success/failure (patient reported)
Notes Patients with severe exacerbations were not included because antibiotics were deemed
indispensable
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Low risk Identical bottles, key to numbers was kept by another person
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical bottles and capsules
31Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Berry 1960 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Practitioners were blinded
Intention-to-treat-analysis High risk Patients with possible toxic effects from drugs were excluded
Daniels 2010
Methods RCT
Participants Participants: hospitalised patients with acute exacerbations of COPD
Inclusion criteria: aged > 45 years, diagnosis of COPD (GOLD criteria), acute exacer-
bation (Anthonisen 1 and 2)
Exclusion criteria: inability to take oral medication, fever (> 38.5 °C), antibiotic treat-
ment for > 24 hours, extensive treatment with corticosteroids (> 30 mg > 4 days), his-
tory of severe exacerbation requiring mechanical ventilation, lung malignancy, other
infectious disease requiring antibiotic therapy, heart failure (NYHA III-IV), apparent
immunodeficiency, impaired renal function (creatinine clearance < 20 mL/min)
Baseline demographics: 223 patients included; 265 exacerbations; mean age 72 years;
59.6% male; mean FEV1 (SD) doxycycline group 43.9% (17.2%), placebo group 46.
9% (18.5%)
Spirometrically confirmed COPD: yes
Severity of exacerbation: moderate to severe
Interventions Mean follow-up: 30 days
Treatment group: 7-day course of oral doxycycline, IV prednisolone taper
Control group: 7-day course of placebo, IV prednisolone taper
Outcomes Primary outcome: clinical response on day 30 (success/failure)
Secondary outcome: clinical success day 10, dyspnoea score, adverse events, mortality
Notes Analysis based on the number of exacerbations and patients (mortality)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated
Allocation concealment (selection bias) Low risk “Allocation sequence was kept in a safe at the hospital phar-
macy”; “study medication was delivered in pre-numbered con-
tainers”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind”
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Daniels 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described (only “double-blind”)
Intention-to-treat-analysis Low risk Analysed as intention to treat and per-protocol (we used only
intention to treat)
Elmes 1957
Methods RCT
Participants Participants: patients were instructed to take antibiotic or placebo without a doctor visit
as soon as new or aggravated respiratory symptoms were present
Inclusion criteria: aged < 65 years, regular employment, productive winter cough for >
3 years, during which time they had at least 2 illnesses with purulent sputum, causing
loss of time from work
Exclusion criteria: other disabling disease
Baseline demographics: 88 patients included; mean 54 age years; 84% male; FEV1 not
stated
Spirometrically confirmed COPD: no
Severity of exacerbation: mild to moderate
Interventions Mean follow-up: 17 days
Treatment group: oxytetracycline 1 g/day orally for 5 to 7 days
Control group: placebo for 5 to 7 days
Outcomes Treatment success/failure (need for further antibiotics)
Time off work
Side effects
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Fisher and Yate’s table of random numbers
Allocation concealment (selection bias) Low risk “Key list was held by the hospitals pharmacist”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Dummy tablets... neither doctors nor patients knowing which
was which”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Dummy tablets... neither doctors nor patients knowing which
was which”
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Elmes 1957 (Continued)
Intention-to-treat-analysis Low risk Analysed as intention to treat
Fear 1962
Methods RCT
Participants Participants: patients recruited from bronchitis and asthma clinics received antibiotic or
placebo as an outpatient based on case of self-reportedworsening of respiratory symptoms
Inclusion criteria: aged 20 to 65 years, winter cough and sputum for at least 3 years, with
shortness of breath on effort without evidence of other cause; some degree of disability
from the bronchitis (e.g. limitation of normal activity, loss of time at work)
Exclusion criteria: none
Baseline demographics: 62 patients included; mean age, % male and FEV1 not stated
Spirometrically confirmed COPD: no
Severity of exacerbation: mild to moderate
Interventions Mean follow-up: 14 days
Treatment group: oxytetracycline 1 g/day (oral) for 7 days
Control group: placebo for 7 days
Outcomes Improvement of symptoms (not analysed in this systematic review)
Days of illness (not analysed in this systematic review)
Notes Second trial of the article
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk List of random numbers
Allocation concealment (selection bias) Low risk “Similar to that used by Elmes 1957” “identical appearance”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind” “identical appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information
Intention-to-treat-analysis Low risk Analysed as intention to treat
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Jørgensen 1992
Methods Randomised double-blind placebo-controlled trial
Participants Participants: patients with general practitioner visits for new or aggravated symptoms
Inclusion criteria: aged > 18 years with acute exacerbation (subjective worsening owing to
change in sputum (increased volume, change of viscosity or colour) possibly accompanied
by cough or dyspnoea, lasting for more than 3 days or chronic bronchitis (defined as
continuous cough and expectoration, present for at least 3 months of the year, in more
than 2 consecutive years)
Exclusion criteria: pneumonia (on auscultation or X-ray), temperature > 38.5 °C, heart
rate > 100 beats/min, antibiotics within the previous 7 days, pregnancy, allergy to peni-
cillin, uncompensated heart disease, treatment with oral corticosteroids or immunosup-
pressants
Baseline demographics: 270 patients included; mean age 60 years, 43% male. FEV1 not
stated
Spirometrically confirmed COPD: no
Severity of exacerbation: mild to moderate
Interventions Mean follow-up: 8 days
Treatment group: amoxicillin 1.5 g (oral) for 7 days
Control group: placebo for 7 days
Outcomes Treatment failure (patient-reported symptoms)
Adverse events
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomised to treatment or
placebo”, with no more details
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not enough information
Intention-to-treat-analysis Low risk Analysed as intention to treat
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Llor 2012
Methods Randomised double-blind, placebo-controlled trial
Participants Participants: recruited from 13 primary care centres
Inclusion criteria: aged >40 years, diagnosis ofmild tomoderateCOPD(smokinghistory
> 10 pack-years, ratio of post-bronchodilator FEV1:FVC of < 70%, post-bronchodilator
FEV1 > 50% of the predicted value), presence of an exacerbation (at least 1 of the
following: increase of dyspnoea, increase in sputum volume, sputum purulence, or a
combination)
Exclusion criteria: antibiotic use in the previous 2weeks, bronchial asthma, cystic fibrosis,
bronchiectasis of origin other than COPD, active neoplasm, tracheotomy, need for
hospital admission, immunosuppression, hypersensitivity to beta-lactams, clavulanate or
lactose, institutionalisation, unable to provide informed consent
Baseline demographics: 310 patients included; mean age 68 years, 81% male, mean
FEV1/FVC 62%
Spirometrically confirmed COPD: yes
Severity of exacerbation: mild to moderate
Interventions Mean follow-up: 20 days
Treatment group: amoxicillin/clavulanate 500/125 mg 3 times daily (oral) for 8 days
Control group: placebo for 8 days
Outcomes Primary outcome: clinical cure/improvement or failure at the end of therapy visit (days
9 to 11, physician assessed)
Secondary outcome: clinical cure/improvement or failure at follow-up visit at day 20
Re-exacerbations (in 1 year - not analysed in this systematic review)
Adverse events
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number table
Allocation concealment (selection bias) Unclear risk Not adequately described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients, investigators and data assessors
were masked to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Patients, investigators and data assessors
were masked to treatment allocation
Intention-to-treat-analysis Low risk Analysed as intention to treat
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Manresa 1987
Methods Randomised double-blind, placebo-controlled trial
Participants Participants: patients admitted to hospital with exacerbation of COPD
Inclusion criteria: at the time of a hospital admission: increase in symptoms (cough,
dyspnoea, and volume and purulence of sputum)
Exclusion criteria: evidence of parenchymal consolidation on chest X-ray or of other
pulmonary or cardiac disease
Baseline demographics: 19 patients included, mean age 67 years, % male, FEV1 not
stated
Spirometrically confirmed COPD: no
Severity of exacerbation: severe
Interventions Mean follow-up: 13 days
Treatment group: cefaclor 1.5 g/day (oral) for 8 days
Control group: placebo for 8 days
Outcomes Length of hospital stay
Notes Research letter to the editor
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described (“double blind”)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described (“double blind”)
Intention-to-treat-analysis Low risk Analysed as intention to treat
Nouira 2001
Methods Randomised, double-blind, placebo-controlled trial
Participants Participants: patients admitted to medical ICU with exacerbation of COPD and need
for mechanical ventilation
Inclusion criteria: aged > 40 years; COPD diagnosed on the basis of clinical history,
physical examination, and chest radiograph; acute respiratory failure requiring mechan-
ical ventilation within the first 24 h of admission
Exclusion criteria: antimicrobial treatment in the previous 10 days, alveolar infiltrates on
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Nouira 2001 (Continued)
chest X-rays, previously enrolled in the study. Known history of asthma or bronchiec-
tasis, allergy to quinolone derivatives, pregnancy or breast feeding, terminally ill or im-
munocompromised, hepatic disease or severe renal impairment, gastrointestinal disease
that could affect drug absorption, concomitant infection requiring systemic antibacterial
therapy
Baseline demographics: 93 patients included; mean age 66 years, 90%male, mean FEV1
0.77 L/s
Spirometrically confirmed COPD: no
Severity of exacerbation: severe
Interventions Mean follow-up: 10 days
All patients were monitored until their discharge from hospital
Treatment group: ofloxacin 400 mg/day (oral) for 10 days
Control group: placebo for 10 days
Outcomes Mortality
Treatment failure (need for additional antibiotics and death combined)
Length of hospital stay
Adverse events
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned to treat-
ment or placebo using random numbers
Allocation concealment (selection bias) Low risk All drugs and placebo packages were pre-
pared and numbered by the hospital phar-
macy and were used consecutively. Assign-
ments of patients were placed in closed en-
velopes with identification numbers that
were stored in the ICU
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical appearance of the medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All study investigators and hospital staff
were masked to the treatment status until
data completion
Intention-to-treat-analysis Low risk Analysed as intention to treat
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Petersen 1967
Methods Randomised, double-blind, controlled trial
Participants Participants: patients admitted to hospital with exacerbation (not defined) of COPD
Inclusion criteria: aged 45 to 75 years, chronic bronchitis (history of cough and expecto-
ration on most days during at least 3 consecutive months in each of 2 or more successive
years)
Exclusion criteria: severe deformities of the spine or chest, localised or generalised specific
lung disease, signs of cardiac insufficiency
Baseline demographics: 19 patients included; mean age 62 years, 53% male
Spirometrically confirmed COPD: no
Severity of exacerbation: severe
Interventions Mean follow-up: 10 days
Treatment group: chloramphenicol 2 g/day for 10 day
Control group: placebo for 10 day
Outcomes Mortality
Patient-reported well-being
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Patients: yes; personnel: no
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Control group got a clinical examination
on day 0
Intention-to-treat-analysis High risk Drop-outswere not analysed (only per-pro-
tocol reported)
Pines 1968
Methods Randomised, double-blinded, placebo-controlled trial
Participants Participants: patients admitted to hospital with exacerbation of symptoms of chronic
bronchitis
Inclusion criteria: > 50 years old, history of chronic bronchitis > 5 years and a history
during the past 6 weeks of an exacerbation, male, moderately-to-severely illness on
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Pines 1968 (Continued)
admission (as judged by the receiving SHO), persistent purulent sputum and a PEFR <
200 L/min (unless too ill to do so)
Exclusion criteria: allergy to penicillin, asthma, extensive bronchiectasis, active tubercu-
losis, lung cancer, sputum eosinophilia (> 10%) or blood urea > 60 mg/100 mL
Baseline demographics: 30 patients, mean age 68 years, 100% males, FEV1 not reported
Spirometrically confirmed COPD: No
Severity of exacerbation: severe
Interventions Mean follow-up: 14 days
Treatment group: penicillin 6 million units/day for 14 days and streptomycin 1 g/day
parenterally for 7 days
Control group: placebo for 14 days
Outcomes Treatment failure (physician reported)
Mortality
Notes Pilot trial of the paper
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Fisher and Yate’s tables
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo injection”, “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “blind assessors”
Intention-to-treat-analysis Low risk Analysed as intention to treat
Pines 1972
Methods Randomised double-blinded controlled trial
Participants Participants: patients admitted to hospital with exacerbation of COPD
Inclusion criteria: aged > 60 years old, history of chronic bronchitis > 5 years and a
definite history during the previous 6 weeks of an exacerbation, male, failure of at least 1
previous treatment with antibiotics, moderately severely ill on admission (as judged by
the receiving SHO), persistent purulent sputum and PEFR < 200 L/min
Exclusion criteria: asthma, bronchiectasis, other pulmonary disease or sputum
eosinophilia (> 10%)
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Pines 1972 (Continued)
Baseline demographics: 259 patients included, mean age 71 years, 100% male, FEV1
not reported
Spirometrically confirmed COPD: no
Severity of exacerbation: severe
Interventions Mean follow-up: 12 days
Exacerbations were followed at the beginning and end of trial and 1 and 4 weeks later
Treatment groups 1 and 2: tetracycline hydrochloride 2 g/day or chloramphenicol 2 g/
day orally for 12 days
Control group: placebo for 12 days
Outcomes Treatment failure (physician reported) day 12
Treatment failure (additional antibiotics) day 7 to 28
Mortality
Adverse events
Notes Patients with very severe exacerbation were not included for ethical reasons
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Fisher & Yate’s tables
Allocation concealment (selection bias) Low risk The total course of capsules for each patient
was put into a sealed bottle by an indepen-
dent pharmacist
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identical capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessments were made by independent
trained observers
Intention-to-treat-analysis Low risk No withdrawals
Sachs 1995
Methods RCT
Participants Participants: patients with general practitioner visit for new or aggravated respiratory
(increase in dyspnoea with or without sputum production) symptoms
Inclusion criteria: aged > 18 years, positive diagnosis of asthma or COPD made by a
pulmonary physician during the previous 10 years
Exclusion criteria: daily use of oral corticosteroids or antimicrobial drugs, diabetes mel-
litus, alcoholism, history of pulmonary surgery or tuberculosis, severe bronchiectasis, a
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Sachs 1995 (Continued)
psychiatric history
Baseline demographics: 61 patients included; mean age ~ 52 years, % male and mean
FEV1 not stated
Spirometrically confirmed COPD: unclear
Severity of exacerbation: mild to moderate
Interventions Mean follow-up: 35 days
Treatment group: amoxicillin 1.5 g or co-trimoxazole 1.9 g/day orally for 7 days
Control group: placebo for 7 days
Outcomes Treatment success/failure (patient reported symptoms)
Notes We included only the subgroup with COPD
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk List of random numbers
Allocation concealment (selection bias) Low risk Hospital pharmacist had the code of allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Intention-to-treat-analysis Low risk Analysed as intention to treat
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; ICU:
intensive care unit; IV: intravenous; NYHA: New York Heart Association; PEFR: peak expiratory flow rate; RCT: randomised
controlled trial; SD: standard deviation; SHO: senior house officer; TLC: total lung capacity; UTI: urinary tract infection.
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Aitchison 1968 No placebo group
Alix 1979 No placebo group
Allan 1966 No placebo group
Allegra 1996 No placebo group
Alvarez-Sala 2006 No placebo group
Andrijevic 2011 No comparison group
Anon 1969 No placebo group
Anon 1972 No placebo group
Banerjee 2001 No COPD exacerbations
Bekçi 2009 Participants did not have an exacerbation of COPD (stable patients)
Bennion-Pedley 1969 No placebo group
Braendli 1982 No placebo group
Burgi 1975 No placebo group
Burrow 1975 No placebo group
Chatterjee 2011 No placebo group
Chen 2000 No placebo group
Christiansen 1963 No placebo group
Citron 1969 Not an RCT
Dong 2005 No placebo group
Douglas 1957 Not randomised and study had no placebo group
Egede 1993 No placebo group
Elmes 1965 Not randomised. Matched pairs
Fartoukh 2004 Protocol. Trial stopped due to recruitment problems
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(Continued)
Filipovic 2000 No placebo group
Francis 1960 Use of long-term prophylactic antibiotics
Francis 1964 No placebo group
Fruensgaard 1972 No placebo group
Gaillat 2007 No placebo group
Gocke 1964 No placebo group
Goddard 2003 Not an RCT
Gomez 2000 Prophylactic antibiotic use. Patients treated with azithromycin 500 mg/day for 3 days every 21 days during
the winter months, and a control group without treatment
Gotfried 2007 No placebo group
Guerin 1987 No placebo group
Haanaes 1980 No placebo group
Hansen 1986 Not an RCT
Hansen 1990 No clinical outcomes
Hauke 2002 No placebo group
Hopkins 1962 No placebo group
Jacobsen 2002 Not an RCT but a retrospective chart review
Jia 2010 No placebo group
Johnston 1961 Study assessed outcomes of long-term antibiotic use in stable patients (no exacerbation)
Kaul 1967 No placebo group
King 1996 Study not in patients with COPD but in patients with acute bronchitis
Leophonte 1998 Study not in patients with COPD but in patients with acute bronchitis
Lirsac 2000 No placebo group. In addition the antibiotic treatment group also received fenspiride (from day 0 to day
30) and the control group received a placebo
Maesen 1976 No placebo group
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(Continued)
Maesen 1980 No placebo group
Malone 1968 No placebo group
May 1964 No placebo group
Miravitlles 2009 Study compared participants with stable disease (no exacerbation)
NCT00255983 This study terminated early (financial reasons)
Nicotra 1982 No clinical outcomes
Nonikov 2001 No placebo group
Parnham 2005 Study looked at participants with stable disease (no exacerbation)
Peng 2003 Not an RCT but a retrospective cohort study
Pham 1964 Not an RCT
Pines 1967 No placebo group
Pines 1969 No placebo group
Pines 1972a No placebo group
Pines 1973 No placebo group
Pines 1973a No placebo group
Pines 1974 Not an RCT
PRITZL 1959 Not an RCT
Puchelle 1975 No placebo group
Pugh 1964 No placebo group
Rethly 1961 Not an RCT
Roede 2007 Placebo group began after 3 days of antibiotics in both groups
Romanovskikh 2007 No placebo group
Ross 1973 No placebo group
Sethi 2007 No placebo group
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(Continued)
Sethi 2010 Study looked at participants with stable disease (no exacerbation)
Smyllie 1972 No placebo group
Sohy 2002 Not an RCT but a narrative review
Soler 2003 No placebo group
Stolz 2007 No placebo group
Suzuki 2001 Prophylactic antibiotic use
Tremolieres 2000 No placebo group
Williams 1981 No placebo group
Wilson 2004 No placebo group in trial. Moxifloxacin was compared to standard antibiotic therapy
Wilson 2011 No placebo group
Wilson 2012 Head-to-head trial of 2 different antibiotics regimens
Zapulla 1988 No placebo group
Zervos 2005 No placebo group
COPD: chronic obstructive pulmonary disease; RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
NCT01091493
Trial name or title Utility of Antibiotic Treatment in Non-purulent Exacerbations of Chronic Obstructive Pulmonary Disease:
a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy (AEPOC-ATB)
Methods RCT
Participants Inclusion criteria: aged 40 to 90 years; COPD diagnosis according to GOLD guidelines; hospitalisation for
any acute exacerbation of COPD; failure of outpatient treatment, increasing dyspnoea in the previous days;
co-morbidity that caused detriment of respiratory function
Exclusion criteria: life expectancy of < 6 months; mechanical ventilation; cardiovascular condition that causes
exacerbation; immunosuppression; pulmonary infiltrates that suggest pneumonia; antibiotic treatment in the
last month; pregnancy; ECG with a large QT segment; hypokalaemia; hepatic failure or renal failure
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NCT01091493 (Continued)
Interventions Drug: moxifloxacin 400 mg administered once a day for 5 days
Control: no intervention
Outcomes Primary outcome measures: efficacy of treatment WITHOUT antibiotics in non-purulent exacerbations of
COPD (time frame: 6 months)
Secondary outcome measures: efficacy/safety in treatment on re-hospitalisations at 6 months (time frame: 6
months); in-hospital stay (days) (time frame: 6 months); all-cause mortality (time frame: 1 and 6 months)
; determination of procalcitonin (time frame: hospitalisation day 1, 1 month and 6 months); quality of life
measured by the St George’s Respiratory Questionnaire (time frame: hospitalisation day 1 and 6 months);
measure of CRP (time frame: hospitalisation day 1, 1 month and 6 months); measure of cytokines (IL-1, IL-
6, IL-8, IL-10) (time frame: hospitalisation day 1, 1 month and 6 months); measure of TNF-α (time frame:
hospitalisation day 1, 1 month and 6 months)
Starting date July 2010
Contact information Nestor Soler, M.D., Ph.D. email:nsoler@clinic.ub.es
Notes -
COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; ECG: electrocardiogram; IL: interleukin; RCT: randomised
controlled trial; TNF-α: tumour necrosis factor-alpha.
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment failure up to 4 weeks
(no resolution or deterioration
after trial medication of any
duration or death when
explicitly stated due to
exacerbation or additional
course of antibiotics)
12 1636 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.62, 0.81]
1.1 Outpatient 7 931 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.60, 0.94]
1.2 Inpatient 4 612 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.65, 0.91]
1.3 ICU 1 93 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.08, 0.45]
2 Treatment failure within 4 weeks
- current drugs only
8 1175 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.64, 0.91]
2.1 Outpatient 5 790 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.63, 1.01]
2.2 Inpatient 3 385 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.55, 0.92]
3 Adverse events 5 Peto Odds Ratio (Peto, Fixed, 95% CI) Subtotals only
3.1 Diarrhoea 3 698 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.62 [1.11, 6.17]
3.2 Dyspepsia 2 605 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.28, 1.73]
3.3 Pain in mouth 1 270 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.73 [0.80, 74.98]
3.4 Exanthema, itching 3 698 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.83 [0.77, 19.11]
3.5 Overall (adverse events
not separated)
5 1243 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.53 [1.03, 2.27]
4 All-cause mortality 5 624 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.54 [0.25, 1.16]
4.1 Inpatients 4 531 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.37, 2.79]
4.2 ICU patients 1 93 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.21 [0.06, 0.72]
5 Duration of hospital stay (days) 3 202 Mean Difference (IV, Random, 95% CI) -3.04 [-8.83, 2.76]
6 Improvement in dyspnoea
measured at the end of the
study period
2 300 Mean Difference (IV, Fixed, 95% CI) -0.40 [-0.96, 0.15]
6.1 Outpatients 1 35 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.97, 0.97]
6.2 Inpatients 1 265 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.27, 0.07]
7 Health-related quality of life or
functional status measures
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Re-exacerbations within ≥ 2
to 6 weeks since beginning of
index exacerbation (rates)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9 Days off work 1 88 Mean Difference (IV, Fixed, 95% CI) -5.18 [-6.08, -4.28]
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Analysis 1.1. Comparison 1 Antibiotics versus placebo, Outcome 1 Treatment failure up to 4 weeks (no
resolution or deterioration after trial medication of any duration or death when explicitly stated due to
exacerbation or additional course of antibiotics).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 1 Treatment failure up to 4 weeks (no resolution or deterioration after trial medication of any duration or death when explicitly stated due to exacerbation
or additional course of antibiotics)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Outpatient
ABC 2009 (1) 3/18 3/17 1.0 % 0.94 [ 0.22, 4.05 ]
Anthonisen 1987 (2) 19/57 28/59 9.2 % 0.70 [ 0.45, 1.11 ]
Berry 1960 0/26 5/27 1.8 % 0.09 [ 0.01, 1.62 ]
Elmes 1957 (3) 4/42 9/46 2.9 % 0.49 [ 0.16, 1.46 ]
J rgensen 1992 (4) 49/132 49/136 16.1 % 1.03 [ 0.75, 1.41 ]
Llor 2012 (5) 15/158 30/152 10.2 % 0.48 [ 0.27, 0.86 ]
Sachs 1995 (6) 4/40 2/21 0.9 % 1.05 [ 0.21, 5.27 ]
Subtotal (95% CI) 473 458 42.0 % 0.75 [ 0.60, 0.94 ]
Total events: 94 (Antibiotics), 126 (Placebo)
Heterogeneity: Chi2 = 9.18, df = 6 (P = 0.16); I2 =35%
Test for overall effect: Z = 2.54 (P = 0.011)
2 Inpatient
Alonso Martinez 1992 4/61 6/29 2.7 % 0.32 [ 0.10, 1.04 ]
Daniels 2010 (7) 50/128 65/137 20.9 % 0.82 [ 0.62, 1.09 ]
Pines 1968 5/15 12/15 4.0 % 0.42 [ 0.20, 0.89 ]
Pines 1972 (8) 93/160 46/67 21.6 % 0.85 [ 0.69, 1.04 ]
Subtotal (95% CI) 364 248 49.2 % 0.77 [ 0.65, 0.91 ]
Total events: 152 (Antibiotics), 129 (Placebo)
Heterogeneity: Chi2 = 5.65, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 3.02 (P = 0.0025)
3 ICU
Nouira 2001 5/47 26/46 8.8 % 0.19 [ 0.08, 0.45 ]
Subtotal (95% CI) 47 46 8.8 % 0.19 [ 0.08, 0.45 ]
Total events: 5 (Antibiotics), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.78 (P = 0.00016)
Total (95% CI) 884 752 100.0 % 0.71 [ 0.62, 0.81 ]
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 251 (Antibiotics), 281 (Placebo)
Heterogeneity: Chi2 = 26.34, df = 11 (P = 0.01); I2 =58%
Test for overall effect: Z = 4.95 (P < 0.00001)
Test for subgroup differences: Chi2 = 9.85, df = 2 (P = 0.01), I2 =80%
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(1) 28 days,
(2) within 21 days
(3) time point unclear;reported for exacerbations only.under the assumption that it happened to every pat once we took patients instead
(4) day 8
(5) 20 days
(6) failure between 4-24 days
(7) day 30
(8) additional antibiotics (day 7-28)
50Antibiotics for exacerbations of chronic obstructive pulmonary disease (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Antibiotics versus placebo, Outcome 2 Treatment failure within 4 weeks -
current drugs only.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 2 Treatment failure within 4 weeks - current drugs only
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Outpatient
ABC 2009 (1) 3/18 3/17 1.6 % 0.94 [ 0.22, 4.05 ]
Anthonisen 1987 (2) 19/57 28/59 14.1 % 0.70 [ 0.45, 1.11 ]
J rgensen 1992 (3) 49/132 49/136 24.8 % 1.03 [ 0.75, 1.41 ]
Llor 2012 (4) 15/158 30/152 15.7 % 0.48 [ 0.27, 0.86 ]
Sachs 1995 (5) 4/40 2/21 1.3 % 1.05 [ 0.21, 5.27 ]
Subtotal (95% CI) 405 385 57.5 % 0.80 [ 0.63, 1.01 ]
Total events: 90 (Antibiotics), 112 (Placebo)
Heterogeneity: Chi2 = 5.93, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 1.91 (P = 0.056)
2 Inpatient
Alonso Martinez 1992 4/61 6/29 4.2 % 0.32 [ 0.10, 1.04 ]
Daniels 2010 (6) 50/128 65/137 32.2 % 0.82 [ 0.62, 1.09 ]
Pines 1968 5/15 12/15 6.2 % 0.42 [ 0.20, 0.89 ]
Subtotal (95% CI) 204 181 42.5 % 0.71 [ 0.55, 0.92 ]
Total events: 59 (Antibiotics), 83 (Placebo)
Heterogeneity: Chi2 = 4.74, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 2.59 (P = 0.0095)
Total (95% CI) 609 566 100.0 % 0.76 [ 0.64, 0.91 ]
Total events: 149 (Antibiotics), 195 (Placebo)
Heterogeneity: Chi2 = 11.13, df = 7 (P = 0.13); I2 =37%
Test for overall effect: Z = 3.10 (P = 0.0020)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
(1) 28 days,
(2) within 21 days
(3) day 8
(4) 20 days
(5) failure between 4-24 days
(6) day 30
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Analysis 1.3. Comparison 1 Antibiotics versus placebo, Outcome 3 Adverse events.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 3 Adverse events
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Diarrhoea
Allegra 1991 2/176 1/159 14.2 % 1.77 [ 0.18, 17.17 ]
J rgensen 1992 13/133 4/137 76.3 % 3.18 [ 1.19, 8.48 ]
Nouira 2001 1/47 1/46 9.4 % 0.98 [ 0.06, 15.89 ]
Subtotal (95% CI) 356 342 100.0 % 2.62 [ 1.11, 6.17 ]
Total events: 16 (Antibiotics), 6 (Placebo)
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
2 Dyspepsia
Allegra 1991 5/176 5/159 52.6 % 0.90 [ 0.26, 3.17 ]
J rgensen 1992 3/133 6/137 47.4 % 0.52 [ 0.14, 1.95 ]
Subtotal (95% CI) 309 296 100.0 % 0.69 [ 0.28, 1.73 ]
Total events: 8 (Antibiotics), 11 (Placebo)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
3 Pain in mouth
J rgensen 1992 3/133 0/137 100.0 % 7.73 [ 0.80, 74.98 ]
Subtotal (95% CI) 133 137 100.0 % 7.73 [ 0.80, 74.98 ]
Total events: 3 (Antibiotics), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
4 Exanthema, itching
Allegra 1991 1/176 0/159 16.8 % 6.71 [ 0.13, 339.81 ]
J rgensen 1992 3/133 1/137 66.4 % 2.83 [ 0.39, 20.34 ]
Nouira 2001 1/47 0/46 16.8 % 7.23 [ 0.14, 364.63 ]
Subtotal (95% CI) 356 342 100.0 % 3.83 [ 0.77, 19.11 ]
Total events: 5 (Antibiotics), 1 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
5 Overall (adverse events not separated)
Allegra 1991 8/168 6/153 13.5 % 1.22 [ 0.42, 3.57 ]
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Daniels 2010 4/133 5/125 8.8 % 0.75 [ 0.20, 2.81 ]
J rgensen 1992 27/133 18/137 38.0 % 1.67 [ 0.88, 3.17 ]
Llor 2012 23/158 12/152 31.4 % 1.94 [ 0.96, 3.92 ]
Nouira 2001 5/42 4/42 8.2 % 1.28 [ 0.32, 5.06 ]
Subtotal (95% CI) 634 609 100.0 % 1.53 [ 1.03, 2.27 ]
Total events: 67 (Antibiotics), 45 (Placebo)
Heterogeneity: Chi2 = 1.87, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours placebo
Analysis 1.4. Comparison 1 Antibiotics versus placebo, Outcome 4 All-cause mortality.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 4 All-cause mortality
Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Inpatients
Pines 1972 0/173 1/86 3.5 % 0.05 [ 0.00, 3.16 ]
Petersen 1967 0/9 1/10 3.9 % 0.15 [ 0.00, 7.58 ]
Pines 1968 1/15 3/15 14.0 % 0.33 [ 0.04, 2.60 ]
Daniels 2010 7/107 3/116 37.4 % 2.51 [ 0.71, 8.90 ]
Subtotal (95% CI) 304 227 58.8 % 1.02 [ 0.37, 2.79 ]
Total events: 8 (Antibiotics), 8 (Placebo)
Heterogeneity: Chi2 = 6.05, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.03 (P = 0.98)
2 ICU patients
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
(Continued . . . )
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Study or subgroup Antibiotics Placebo
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Nouira 2001 2/47 10/46 41.2 % 0.21 [ 0.06, 0.72 ]
Subtotal (95% CI) 47 46 41.2 % 0.21 [ 0.06, 0.72 ]
Total events: 2 (Antibiotics), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.50 (P = 0.012)
Total (95% CI) 351 273 100.0 % 0.54 [ 0.25, 1.16 ]
Total events: 10 (Antibiotics), 18 (Placebo)
Heterogeneity: Chi2 = 9.80, df = 4 (P = 0.04); I2 =59%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Chi2 = 3.75, df = 1 (P = 0.05), I2 =73%
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
Analysis 1.5. Comparison 1 Antibiotics versus placebo, Outcome 5 Duration of hospital stay (days).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 5 Duration of hospital stay (days)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Alonso Martinez 1992 61 7.9 (2.1) 29 8.1 (2.4) 35.8 % -0.20 [ -1.22, 0.82 ]
Manresa 1987 11 12.8 (4) 8 12.3 (4) 31.7 % 0.50 [ -3.14, 4.14 ]
Nouira 2001 47 14.9 (7.4) 46 24.5 (8.5) 32.5 % -9.60 [ -12.84, -6.36 ]
Total (95% CI) 119 83 100.0 % -3.04 [ -8.83, 2.76 ]
Heterogeneity: Tau2 = 24.14; Chi2 = 30.03, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.03 (P = 0.30)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours antibiotic Favours placebo
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Analysis 1.6. Comparison 1 Antibiotics versus placebo, Outcome 6 Improvement in dyspnoea measured at
the end of the study period.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 6 Improvement in dyspnoea measured at the end of the study period
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Outpatients
ABC 2009 18 0.5 (1.3) 17 0.5 (1.6) 32.6 % 0.0 [ -0.97, 0.97 ]
Subtotal (95% CI) 18 17 32.6 % 0.0 [ -0.97, 0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Inpatients
Daniels 2010 128 -2.4 (2.8) 137 -1.8 (2.8) 67.4 % -0.60 [ -1.27, 0.07 ]
Subtotal (95% CI) 128 137 67.4 % -0.60 [ -1.27, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
Total (95% CI) 146 154 100.0 % -0.40 [ -0.96, 0.15 ]
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 0.99, df = 1 (P = 0.32), I2 =0.0%
-2 -1 0 1 2
Favours Antibiotics Favours control
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Analysis 1.7. Comparison 1 Antibiotics versus placebo, Outcome 7 Health-related quality of life or
functional status measures.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 7 Health-related quality of life or functional status measures
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
ABC 2009 (1) 18 -2.3 (2.7) 17 -2.3 (2.7) 0.0 [ -1.79, 1.79 ]
-4 -2 0 2 4
Favours antibiotics Favours control
(1) CCQ
Analysis 1.8. Comparison 1 Antibiotics versus placebo, Outcome 8 Re-exacerbations within ≥ 2 to 6 weeks
since beginning of index exacerbation (rates).
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 8 Re-exacerbations within≥ 2 to 6 weeks since beginning of index exacerbation (rates)
Study or subgroup Antibiotics Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ABC 2009 (1) 2/18 1/17 1.89 [ 0.19, 18.97 ]
0.01 0.1 1 10 100
Favours Antibiotics Favours control
(1) relapse within 4 weeks
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Analysis 1.9. Comparison 1 Antibiotics versus placebo, Outcome 9 Days off work.
Review: Antibiotics for exacerbations of chronic obstructive pulmonary disease
Comparison: 1 Antibiotics versus placebo
Outcome: 9 Days off work
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Elmes 1957 42 4.25 (0.96) 46 9.43 (2.96) 100.0 % -5.18 [ -6.08, -4.28 ]
Total (95% CI) 42 46 100.0 % -5.18 [ -6.08, -4.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.24 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours antibiotics Favours control
A D D I T I O N A L T A B L E S
Table 1. Type and dose of antibiotic used
Study Antibiotic Dose Duration Currently avail-
able and used?
Co-interventions Control
ABC 2009 Amoxicillin-
clavulanic acid
(oral)
1.5 g/day 7 days Yes Oral prednisolone
30 mg for 7 days
Placebo for 7
days and oral pred-
nisolone 30 mg for
7 days
Allegra 1991 Amoxicillin-
clavulanic acid
(oral)
2 g/day 5 days Yes Placebo
Alonso Martinez
1992
Trimethoprim-
sulphamethox-
azole or amoxi-
cillin/clavulanic
acid
1.9 g/day 8 days Yes
Anthonisen
1987
Trimethoprim/
sulphamethoxa-
zole (oral)
1.9 g/day 10 days Yes Placebo
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Table 1. Type and dose of antibiotic used (Continued)
Amoxicillin
(oral)
1 g/day
Doxycycline
(oral)
0.1 to 0.2/day
Berry 1960 Oxytetracycline
(oral)
1 g/day 5 days No Placebo
Daniels 2010 Doxycycline
(oral)
7 days Yes IV prednisolone ta-
per
Placebo plus IV
prednisolone taper
Elmes 1957 Oxytetracycline
(oral)
1 g/day 5 to 7 days No Placebo
Fear 1962 Oxytetracycline
(oral)
1 g/day 7 days No placebo
Jørgensen 1992 Amoxicillin
(oral)
1.5 g/day 7 days Yes placebo
Llor 2012 Amoxicillin/
clavulanate
(oral)
1.5 g/day 8 days Yes Placebo
Manresa 1987 Cefaclor (oral) 1.5 g/day 8 days Yes placebo
Nouira 2001 Ofloxacin (oral) 400 mg/day 10 days Yes placebo
Petersen 1967 Chlorampheni-
col (oral)
2 g/day 10 days No placebo
Pines 1968 Penicillin
(parenterally)
1 g/day 14 days Yes placebo
Pines 1972 Tetracycline hy-
drochloride
(oral) or Chlo-
ramphenicol
2 g/day 12 days No placebo
Sachs 1995 Amoxicillin 1.5
g/day 1.9 g/day
(oral)
1.5 g/day 7 days yes placebo
or co-
trimoxazole
1.9 g/day
IV: intravenous.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (T he Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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MEDLINE search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We had to change our primary outcome from treatment failure within two weeks to four weeks because the reporting of the time of
the end point was too heterogeneous.
Some outcomes were not reported at all (hospital admission, admission to an ICU).
We did not analyse subgroups on duration of antibiotic intervention or type of antibiotic intervention because the number of studies
was too small.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Ambulatory Care; Anti-Bacterial Agents [adverse effects; ∗therapeutic use]; Disease Progression; Hospitalization; Intensive Care Units;
Pulmonary Disease, Chronic Obstructive [classification; ∗drug therapy; mortality]; Randomized Controlled Trials as Topic; Treatment
Failure
MeSH check words
Humans
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